ATS/Alpha-1 Foundation Research Grant

ALA/ATS/CHEST Foundation Respiratory Health Equity Research Award

• The first award is intended to support investigators that will address topics on improving clinical outcomes in preventing and/or treating lung disease in groups disproportionately impacted.
  
  
• The second award is intended to support an investigator who is a person of color that is doing clinical research in a pulmonary disease that disproportionately affects communities of color. 

The focus of these research grants is clinical research that addresses topics on improving clinical outcomes in preventing and/or treating lung disease that disproportionately affects under-represented minority (URM) patient groups. URM patient groups includes patients from lower-middle- and low-income countries as defined by the World Bank, or the following North American populations: African Americans, Mexican-Americans, Native Americans (American Indians, Alaska Natives, and Native Hawaiians), Pacific Islanders, and mainland Puerto Ricans.  

Applicants may request up to $100,000 per year for two years for salaries, supplies, or a combination of these two. No more than 20% of the budget can be for salary. Indirect costs will not be paid to the sponsoring institution.

Recipients will also be eligible for complimentary registration and a $1,000 travel stipend to attend both the ATS International Conference and CHEST Annual Meeting up to one year past conclusion of the research to present data.

• Must be US citizens or hold a Visa that spans the project period of the grant
• Early-stage investigators (as defined here) and applicants who are trainees (fellows)
• Applicants holding PhD, MD, RN, RRT, or PA degrees
• Must be a member of the ATS and CHEST
• Must meet eligibility requirements for all grants found here

ATS/COPD Foundation Research Grant

The focus of this research grant is proposals that have a high likelihood to advance the understanding of the pathophysiology of non-CF Bronchiectasis. Applicants may request up to $40,000 per year for two years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution

ATS/Fisher & Paykel Healthcare Research Grant in Nasal High Flow

1 grant available
$50,000 for 1 year

Target Audience:
Early-stage investigators interested in research on respiratory support with nasal high flow therapy for hospital patients

The focus of this research grant is proposals on respiratory support with nasal high flow therapy for hospital patients. Nasal high flow (NHF) therapy refers to a typical range from 20 to 70 L/min of heated, humidified gas delivered to the nares via purposely designed nasal cannula. Flow settings and fraction of delivered supplemental oxygen during the therapy vary depending on the patient’s level of compliance and severity of disease. There has been a recent rapid uptake in the use of NHF in acute care settings, primarily to treat hypoxemic respiratory failure, and the therapy has been extensively used around the world during the COVID-19 pandemic. Apart from efficient oxygenation due to the prevention of room air entrainment, NHF provides respiratory support that may be seen in the reduction of the breathing frequency and the work of breathing. Positive airway pressure and the reduction of re-breathing caused by the clearance of expired gas in the upper airways are believed to be the key mechanisms that may improve the ventilation efficiency during NHF. Saturation with water of heated gas maintains hydration of the airway surface liquid and preserves mucociliary function.

NHF therapy is increasingly used in stable patients with lung disease or post-surgery who require support during unassisted breathing with little or no supplemental oxygen. Fisher & Paykel Healthcare, in collaboration with the American Thoracic Society, seeks to offer a research award to investigators interested in studying these potential benefits of NHF. The prospective study could be aimed at better understanding the mechanisms of action of this therapy, or on achieving improvements in a variety of likely outcomes. 

Applicants may request up to $50,000 for 1 year. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution.

Award-specific eligibility: 
• Early-stage investigators (as defined here) 
• Must meet eligibility requirements for all grants found here

Fully funded by Fisher & Paykel Healthcare.

ATS/Foundation for Sarcoidosis Research Grant

The focus of this research grant is proposals that advance research in the area of sarcoidosis. Applicants may request up to $25,000 per year for two years. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or for subject enrollment fees directly related to the project or other allowable costs. Indirect costs will not be paid to the sponsoring institution.